We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sensor Array System Detects Cancer Types

By LabMedica International staff writers
Posted on 01 Oct 2012
A rapid, sensitive way to detect microscopic levels of many different metastatic cell types in living tissue has been developed. More...


A sensor array of gold nanoparticle sensors plus green fluorescent protein (GFP) that activates in response to patterns in the proteins found in cancer cells within minutes, assigning a unique signature to each cancer.

Chemists at the University of Massachusetts Amherst (MA, USA) used a preclinical non-small-cell lung cancer-metastasis model in mice to develop the system. The new work builds an earlier development of a "chemical nose" array of nanoparticles and polymers able to differentiate between normal cells and cancerous ones.

For this work, the scientists took healthy tissue and mouse tumor samples and trained the nanoparticle-GFP sensor array to recognize them and the GFP to fluoresce in the presence of metastatic tissue. Metastases are differentiated from healthy tissue in a matter of minutes, providing a rapid and very general means of detecting and identifying cancer and potentially other diseases using minimally invasive microbiopsies.

In addition to the high sensitivity, the sensor is able to differentiate between low (parental) and high (bone, adrenal, and ovary) metastases, as well as between site-specific cells such as breast, liver, lung and prostate cancers. Until now, the standard method for precisely identifying cancer cells used a biological receptor approach, a protein binding to a cancer cell wall. Its major drawback is that one must know the appropriate receptor beforehand. Array-based sensing approaches discriminate between analytes based on their overall signatures and are emerging as a potential alternative for point-of-care diagnosis.

The authors concluded that the sensor created a distinct fingerprint pattern for the normal and metastatic tumor tissues. Moreover, this array-based approach is unbiased, precluding the requirement of a priori knowledge of the disease biomarkers. Taken together, these studies demonstrate the utility of this sensor for creating fingerprints of cells and tissues in different states and present a general platform for rapid screening amenable to fine needle-aspiration samples. Overall, the authors concluded that this array-based sensing strategy presents the prospect of unbiased phenotype screening of tissue states arising from genetic variations and differentiation state. The study was published on August 26, 2012, in the journal American Chemical Society Nano (ACS Nano).

Related Links:
University of Massachusetts Amherst




New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
HPV Molecular Test
BD Onclarity HPV Assay
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.